• Skip to primary navigation
  • Skip to main content
  • Skip to primary navigation
  • Skip to main content
Choose which site to search.
University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Translational Research Institute
  • UAMS Health
  • Jobs
  • Giving
  • About TRI
    • What We Offer
    • Leadership & Governance
    • Staff
    • Citing Translational Research Institute CTSA Support
    • What is Translational Research?
    • Contact TRI
  • Funding Opportunities
    • Grants
      • Pilot Award Program
      • Consortium of Rural States (CORES) Multi-Institutional Pilot Award Program
      • Team Science Voucher Program
      • Winthrop P. Rockefeller Cancer Institute Rural Research Award Program
    • Scholarships
      • K12 Mentored Research Career Development Scholar Awards Program
      • Health Sciences Innovation and Entrepreneurship Postdoctoral Training Program
      • Implementation Science Scholar Program
      • (STARs) Program – Strategies for Training and Advancing Researchers
      • SMART Program [Master’s in Clinical and Translational Sciences (MS-CTS)]
    • Community
      • Community Based Participatory Research (CBPR) Scholars Program
      • Community Partners Educated as Arkansas Research Leaders (CPEARL) Program
    • Awardee Responsibilities
  • Services & Resources
    • Services
      • Biostatistics, Epidemiology and Research Design (BERD) Consultation
      • Clinical Data Repository (AR-CDR)
      • Comprehensive Informatics Resource Core
      • Mock Study Sections
      • Research Participant Recruitment
      • Research Support: Clinical Trials Innovation Unit (CTIU)
      • Implementation Science Program
      • Research Ethics Consultation
    • Resources
      • ARresearch Registry
      • Center for Health Literacy
      • Data Safety Monitoring
      • Grant Writing & Dissemination
      • UAMS Profiles
      • UAMS Rural Research Network
      • Other Resources
      • COVID-19 Research Guidelines
      • Community Partner Research Training
  • Career Development & Scholarships
    • Scholarship Opportunities
      • K12 Mentored Research Career Development Scholar Awards Program
      • Health Sciences Innovation and Entrepreneurship Postdoctoral Training Program
      • Data Science Scholars Program
      • Implementation Science Scholar Program
      • SMART Program
      • Translational Research Innovations and Partners (TRIP) Program
    • Training & Educational Opportunities
      • innOVATION Seminar Series
      • Path 2 K Program
      • Translational Workforce Development
      • Graduate Certificate in Implementation Science
      • SMART Program [Master’s in Clinical and Translational Sciences (MS-CTS)]
      • Good Clinical Practice Training
    • Didactic Training
  • Community
    • Community Engagement Leadership
    • Community Advisory Board
    • Community Engagement Partners
      • Community Partner Celebration
      • Faith-Academic Initiatives for Transforming Health (FAITH) Network
    • Community Engagement Services
      • Consultations and Technical Assistance
      • Community Review Boards
      • Community Partner Research Training
      • Equipment Library
    • Programs and Funding
      • Community Partners Educated as Arkansas Research Leaders (CPEARL) Program
      • Community Based Participatory Research (CBPR) Scholars Program
      • Community Scientist Academy
    • Toolkits
      • CSA Online Toolkit
      • CPEARL Toolkit
  • Events
    • Research Day
    • Clinical Trials Learning Collaborative
  • Newsroom
  1. University of Arkansas for Medical Sciences
  2. Translational Research Institute
  3. News
  4. Page 11

News

UAMS Seeks Community Input on Trauma Study

The University of Arkansas for Medical Sciences (UAMS) is consulting the people of central Arkansas whether to lead a local trauma research study to investigate a blood clotting agent as a treatment for trauma patients who are bleeding to death.

Bleeding out is the most common cause of preventable death after injury. Researchers at the University of Arkansas for Medical Sciences (UAMS) are asking for community input on whether they should participate in an international study. The study will see if a blood clotting drug, given soon after arrival in the emergency department, can improve survival.

Kcentra® (or 4-factor Prothrombin Complex Concentrate) is a Food and Drug Administration (FDA) approved drug and is currently used to reverse the effects of medications given to “thin” the blood, for patients who experience bleeding and/or require surgery. 

The Trauma and Prothrombin Complex Concentrate or TAP Trial will evaluate the effectiveness of Kcentra®, in addition to all standard care, in injured patients predicted to require a large volume blood transfusion. “There is evidence that Kcentra® may reduce the chance of dying in injured patients who are not on blood-thinning medications,” said Kyle Kalkwarf, M.D., UAMS trauma medical director and the UAMS principal investigator on the study.

“The standard treatment of injured patients who are bleeding involves the transfusion of different types of blood products, as well as the use of medications to help the blood clot better, along with surgery to stop the bleeding. But even with these treatments up to 30% of patients suffering from a serious traumatic injury die,” Kalkwarf said. “Finding a way to improve that survival rate is our highest priority here at UAMS.”

Patients in this study will have suffered a serious and potentially life-threatening injury, causing significant blood loss, and requiring immediate lifesaving interventions. These types of injuries occur unexpectedly, and it will not be possible for most people to sign up to participate ahead of time. Most patients will be unconscious, unable to speak or hear, and too sick to consent to immediate treatment, or participation in the study.

If the community feedback is positive and an independent review board (IRB) approves the study at UAMS, then UAMS will participate in this trial. Community members who do not want to participate can request a bracelet indicating this. If feasible, doctors will consent patients who fit the study criteria. If consent is not feasible, patients who fit the criteria will be automatically enrolled without their individual consent if they are not wearing an opt-out bracelet.

The TAP trial will be conducted in about 120 leading trauma centers in several countries and will include 8,000 patients, making it the second-largest trauma trial ever conducted. The trial will begin between early 2023 and last until 2026, and is funded by CSL Behring, a global biotherapeutics leader which makes PCC.

“The results of this study have the potential to change the way trauma patients are treated,” Kalkwarf said. “If we can determine that Kcentra® is safe and effective for trauma patients, we can transform the standard of care for bleeding trauma patients and save thousands of lives.”

The researchers are asking for feedback from the central Arkansas community about this study to help determine whether the community wants us to participate in this study. Please consider completing a very brief anonymous survey hosted by the local study site. To complete the anonymous survey on your thoughts about this exception from informed consent study, please go to this link.

Contact:

UAMS Study Team

501-398-8622

TRIcoordinators@uams.edu

Filed Under: News

Christi Madden, MPA, Named Executive Director of Translational Research Institute

Christi Madden, MPA, has joined the UAMS Translational Research Institute as its executive director.

Christi Madden, MPA
Christi Madden, MPA

Madden, a leader with more than two decades of research programmatic management experience, spent most of her career in her home state of Oklahoma at the University of Oklahoma Health Sciences Center (OUHSC), where she worked in the Department of Pediatrics and at the Oklahoma Clinical and Translational Science Institute.

As executive director, Madden oversees all Translational Research Institute staff and services to UAMS researchers. She also serves as a liaison to the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH), which funds the UAMS Translational Research Institute with a Clinical and Translational Science Award (CTSA).

“We are thrilled to have Christi on our team,” said institute Director Laura James, M.D. “In her roles at OUHSC, she managed several highly impactful public health research and quality improvement programs. Her skillset and research leadership experience will help our institute provide the highest quality service to our researchers and to our research participants.”

Madden’s management experience includes the IDeA States Pediatric Clinical Trials Network, the Oklahoma Primary Healthcare Improvement Cooperative, the Oklahoma Child Health Research Network and the Healthy Hearts for Oklahoma project.

She has also worked on several projects with rural communities across Oklahoma to implement community-driven initiatives to improve cardiovascular health, increase access to health care and mental health resources, and implement COVID-19-related research.

In 2022, she was recognized by the Public Health Institute of Oklahoma as one of the County Health Improvement Organization’s Top Ten People of the Decade.

“I am excited to be in this new role at TRI and look forward to working collaboratively across UAMS and with our partners such as Arkansas Children’s Research Institute and the Central Arkansas Veterans Healthcare System to improve the health and health care of Arkansans.” 

The Translational Research Institute is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health, Clinical and Translational Science Award TR003107.

Filed Under: Front, News, Newsroom

The TRIbune Is Here!

Nakita Lovelady, Ph.D. (right), shares a laugh with Melissa Zielinski, Ph.D., during the Research Day poster session.
Nakita Lovelady, Ph.D. (right), shares a laugh with Melissa Zielinski, Ph.D., during the Research Day poster session.

In this month’s TRIbune newsletter, we feature our second annual TRI Research Day, which drew about 150 people from the UAMS research community, including Arkansas Children’s and the Central Arkansas Veteran’s Healthcare System.

Eight of our TRI-supported researchers gave oral presentations, and there were 33 poster presentations. Our keynote speaker was the University of Florida’s Duane A. Mitchell, M.D., Ph.D., a pioneer in the research of brain tumor immunotherapies.

The TRI Study of the Month features Clare Nesmith, M.D., the UAMS principal investigator on a national study comparing rapid and slow weaning methods for newborns with neonatal opioid withdrawal symptoms (NOWS). Read The TRIbune.

Filed Under: Front, News, Newsroom

UAMS’ Laura James, M.D., Re-Elected to National Science Board

LITTLE ROCK — Laura James, M.D., director of the UAMS Translational Research Institute, has been elected to a second term on the national Association for Clinical and Translational Science (ACTS) Board of Directors.

Laura James, M.D.
Laura James, M.D.

She joins 13 other directors at large from National Institutes of Health (NIH)-funded Clinical and Translational Science Awards (CTSA) Program institutions across the United States. She was first elected to the board in 2020.

James has been director of the Translational Research Institute since 2014 and is UAMS associate vice chancellor for Clinical and Translational Research. She has a 28-year history of translational research in clinical pharmacology and toxicology at UAMS and Arkansas Children’s Hospital. As a clinician-scientist and founder of the startup company Acetaminophen Toxicity Diagnostics LLC, she is leading development of a rapid diagnostic test for acetaminophen liver injury. In 2014 she was named an inaugural fellow of the Arkansas Research Alliance (ARA).

The role of the ACTS board is to govern, establish policy and make strategic decisions about the future of the organization. ACTS supports research that continually improves team science, integrating multiple disciplines across the translational science spectrum. It is also the academic home for translational research education and career development, and is an advocate for translational science.

“It has been a pleasure over the last three years working with the ACTS board and staff to create new programs and maximize investments that support the professional development of translational researchers,” James said. “I am excited to continue this work building productive collaborations across the association and with other relevant organizations.”

Translational research is the process of taking findings and discoveries (new medicines, health interventions, etc.) and “translating” or applying them to everyday practices that improve health.

The CTSA Program is administered by the National Center for Advancing Translational Sciences (NCATS) at the NIH. TRI received a five-year, $24.2 million CTSA, grant UL1 TR003107 in July 2019 and is one of more than 60 CTSA-supported institutions nationally.

Filed Under: Front, News, Newsroom

Join Us April 4 for TRI’s Second Annual Research Day!

Come see how we’re translating research into health practice at TRI Research Day 2023 on Tuesday, April 4, from 10 a.m. to 4 p.m. at Heifer International headquarters in Little Rock.

Duane Mitchell, M.D., Ph.D.

Our keynote speaker (11:10 a.m. – noon) is Duane Mitchell, M.D., Ph.D., professor of neurosurgery and director of the University of Florida Clinical Translational Science Institute (CTSI). He is also assistant vice president for research and associate dean for Clinical and Translational Sciences at the UF College of Medicine.

The event will showcase TRI-supported researchers with oral presentations from TRI’s KL2 Mentored Research Career Development scholars, Implementation Science scholars, TL1 Health Science Innovation and Entrepreneurship trainees, and Pilot Award Program awardees.

A poster session, awards and networking are from 2:50 – 4 p.m., and will include the full array of TRI-supported projects across its funding and training programs.

Register here.

Contact: Chaz England, CEngland@uams.edu

Filed Under: Front, News, Newsroom

TRI Study of the Month

Deanne King, M.D., Ph.D., (left) meets with TRI’s Kennetha Newman, the study’s lead research coordinator.
Deanne King, M.D., Ph.D., (left) meets with TRI’s Kennetha Newman, the study’s lead research coordinator.

UAMS Principal Investigator: Deanne L. King, M.D., Ph.D., assistant professor and director of Clinical Research, College of Medicine Department of Otolaryngology – Head & Neck Surgery

Summary: A phase 3 multi-center trial will evaluate the safety and efficacy of a new drug candidate for Meniere’s disease.

Significance: There are few treatment options available for Meniere’s disease, a common inner ear disease whose symptoms include hearing loss, dizziness/vertigo and tinnitus. The anti-inflammatory drug candidate has shown promise as a treatment in smaller studies.

TRI Services: Medicare coverage analysis, study budget development, regulatory and nurse/clinical coordinator support, administration of Clinical Trial Management System, and post-award financial management.

Sponsor: Sound Pharmaceuticals Inc.

Filed Under: Front, News, Newsroom

TRI Advances Computer-Guided Study Consent Forms

Members of the Informed Consent Navigator team include (front, l-r) Mathias Brochhausen, Ph.D., Nicki Spencer, M.H.A., Alison Caballero, MPH, CHES, and Jonathan Bona, Ph.D.; (back row) Justin Whorton, Sarah Fountain, MPH, CPH, CHES, Jennifer Gan-Kemp, MBA, CRS, and Aaron Kemp, MBA. Image by Bryan Clifton
Members of the Informed Consent Navigator team include (front, l-r) Mathias Brochhausen, Ph.D., Nicki Spencer, M.H.A., Alison Caballero, MPH, CHES, and Jonathan Bona, Ph.D.; (back row) Justin Whorton, Sarah Fountain, MPH, CPH, CHES, Jennifer Gan-Kemp, MBA, CRS, and Aaron Kemp, MBA. Image by Bryan Clifton

A new software tool developed at the University of Arkansas for Medical Sciences (UAMS) will help researchers quickly create consent documents in plain language for their prospective study volunteers.

Laura James, M.D.
Laura James, M.D.

Called the Informed Consent Navigator, the web-based tool breaks new ground with its ability to guide researchers through the creation of plain-language informed consent forms at an eighth-grade reading level or below. The Journal of Clinical and Translational Science published the Translational Research Institute team’s work in December, drawing immediate interest from several research institutions across the United States.

“This is a big achievement for UAMS,” said co-author Mathias Brochhausen, Ph.D., a professor in the College of Medicine Department of Biomedical Informatics.

Interdisciplinary Research
First-author Jonathan Bona, Ph.D., led creation of the computer-guided navigation as part of an interdisciplinary research team that includes biomedical informaticists, software developers, research ethicists, and experts in community engagement, health literacy, health education, plain-language writing, clinical trials and informed consent.

“What has been really novel and beneficial is working with folks from across UAMS to make this the best possible tool for researchers and the community,” said Bona, an assistant professor in the College of Medicine’s Department of Biomedical Informatics.

The team was assembled and supported by UAMS Translational Research Institute Director Laura James, M.D., a co-author.

“This project truly played to UAMS’ strengths and is a testament to multidisciplinary team science and the vital support of the Translational Research Institute,” said Brochhausen. “In addition to the institute’s financial support, Dr. James and her team have been with us in the trenches, attending our meetings and helping connect us to key resources.”

Ensuring Readability
Consent forms are often long, detailed, and introduce new concepts, said co-author Alison Caballero, MPH, CHES, director of the Center for Health Literacy. The forms can be a barrier to conducting research, especially in populations with limited health literacy.

“Using language that is readable, understandable and actionable is a challenge, but it is essential for truly informed consents and ensuring our research includes a genuine cross-section of the population,” said Caballero, an associate professor.

While other institutions across the U.S. have been working on similar automated consent processes, UAMS appears to be first with its automated plain-language consents, Brochhausen said.

The Informed Consent Navigator builds on years of work by a collaborative team including the UAMS Center for Health Literacy, which created a plain-language consent form template and made it available to all researchers. Plain-language experts at the center created a large bank of text that is approved by the UAMS Institutional Review Board and covers a broad range of research. Now part of the navigator, the text is automatically populated in the informed consent form based on the user’s answers to questions presented by the navigator.

Where researchers must write original text about their specific studies, the navigator provides instructional text, content examples and real-time feedback with readability scores and suggestions to improve readability.

The navigator also uses survey logic that helps tailor what researchers see as they are guided through the process, reducing the difficulty and eliminating errors often made when using print-based templates.

“The goal for this is not just to make it easier for researchers to build forms, but to do so in a way that checks and encourages — and in some cases enforces — that the forms are readable,” Bona said.

Next Steps
The team plans to pilot the Informed Consent Navigator with clinical research studies at UAMS and other institutions. Prior to that, the latest version of the navigator will be presented to a Community Review Board made up of community representatives recruited by the Translational Research Institute’s Community Engagement team.

“Having community reviewers tell us what is clear and what is not clear is very useful,” Bona said, noting that the community board has given its feedback twice before. “We’ve had great communication with the board and their input has already led to improvements in the navigator.”

Longer term, the team will establish an electronic consenting platform (e-consent). It will also work toward artificial intelligence-powered management of consents to expand the navigator’s functionality.

Bona said the team ultimately hopes to see the navigator deployed at research institutions across the U.S. and beyond with the ability to query the network’s data.

Filed Under: Front, News, Newsroom

Read the Latest TRIbune

Antiño Allen, Ph.D., (right) was among five UAMS research leaders who completed mentorship facilitator training at the University of Wisconsin-Madison.
Antiño Allen, Ph.D., (right) was among five UAMS research leaders who completed mentorship facilitator training at the University of Wisconsin-Madison.

In this month’s issue of The TRIbune, we feature some significant new efforts in mentorship training for researchers. TRI-supported research leaders have received mentorship facilitator training and will be conducting regular, evidence-based mentor training courses for UAMS-affiliated faculty. TRI’s mentorship training efforts reflect a priority of the National Center for Advancing Translational Sciences (NCATS) at the NIH.

The TRI Study of the Month features Jill Mhyre, M.D., professor and chair, College of Medicine Department of Anesthesiology, who is collaborating with Ronda Henry-Tillman, M.D., chief of Breast Surgical Oncology. 

Read The TRIbune.

Filed Under: Front, News, Newsroom

TRI Seeking Letters of Intent from Prospective KL2 Scholar Award Applicants

KL2 Program logo-art

The Translational Research Institute (TRI) is pleased to invite Letters of Intent (LOIs) for the 2023 KL2 Mentored Research Career Development Scholar Awards.

The TRI Mentored Research Career Development Scholars Program provides support for early-career UAMS faculty with a professional degree (M.D., Ph.D., Pharm.D., D.N.P., Dr.PH., D.O., etc.) who are committed to an academic career in multidisciplinary clinical or translational research.

Successful applicants will begin the two-year program July 1, 2023. The KL2 program combines an innovative educational program with mentored clinical/translational science research. KL2 Scholars receive:

Salary support/stipend of up to $95,000 (including fringe) per year.

Up to $25,000 of non-salary support per year, which can be used for research, tuition, travel expenses, educational materials and other costs related to the scholar’s research.

The deadline for submitting LOIs is Friday, Jan. 27, 2023, 5 p.m. (CT).

See attached LOI Cover Page.

View the Request for Applications.

The KL2 program is supported by the Clinical and Translational Science Awards (CTSA) Program of the NIH National Center for Advancing Translational Sciences. Contact: Chaz England, CEngland@uams.edu.

Filed Under: Front, News, Newsroom

SAVE THE DATE: Join Us April 4 for TRI Research Day!

Image art includes the words, Research Day and Translational Research Institute

All are invited to TRI Research Day on Tuesday, April 4, from 10 a.m. to 4 p.m. at Heifer International in Little Rock.

Our keynote speaker is Duane Mitchell, M.D., Ph.D., professor of neurosurgery and director of the University of Florida Clinical Translational Science Institute (CTSI). He is also assistant vice president for Research and associate dean for Clinical and Translational Sciences at the UF College of Medicine.

The event will showcase TRI-supported research with oral presentations from select TRI-supported investigators. A poster session (with prizes!) will include an array of TRI-supported projects across its range of funding and training programs.

Please mark your calendars and stay tuned for registration and other details.

Contact: Robin Liston, rliston@uams.edu.

Filed Under: Front, News, Newsroom

  • «Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Interim pages omitted …
  • Page 48
  • Next Page»
Translational Research Institute LogoTranslational Research InstituteTranslational Research Institute
Mailing Address: 4301 West Markham Street, Little Rock, AR 72205
Phone: (501) 686-7000
  • Facebook
  • X
  • Instagram
  • YouTube
  • LinkedIn
  • Pinterest
  • Disclaimer
  • Terms of Use
  • Privacy Statement
  • Legal Notices

© 2026 University of Arkansas for Medical Sciences